Ipsen is paying $450 million upfront to buy U.S.-based Kartos Therapeutics for a phase 3-stage blood cancer drug designed to improve on Jakafi treatment. The acquisition of Kartos gives the French biopharma access to an oral MDM2 inhibitor called navtemadlin. The drug is aimed at restoring the function of p53, a critical tumor suppressor in myelofibrosis. The p53 protein is already well known for its ability to protect against cancer by preventing DNA-damaged cells from replicating. Last year, PMV Pharmaceuticals reported a 43% response rate in a mid-phase ovarian cancer trial for its p53 reactivator rezatapopt.
Read the full article: Ipsen Pens $1.7B Deal to Acquire Kartos for Potential Jakafi Add-On Therapy for Myelofibrosis //
Source: https://www.fiercebiotech.com/biotech/ipsen-pens-17b-deal-acquire-kartos-potential-jakafi-add-therapy-myelofibrosis